BioSpace News Archive

Business

Employer Direct partners with Coca-Cola Consolidated

Employer Direct Healthcare is excited to announce its partnership with Coca-Cola Consolidated

January 3, 2019
·
2 min read
Deals

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Neovasc announced today that it has received written notification notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.

January 3, 2019
·
9 min read
Biotech Bay

REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019

REVOLUTION Medicines, Inc., a biotechnology company that translates frontier oncology targets to outsmart cancer, today announced that it will make a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

January 3, 2019
·
2 min read
Business

GI Dynamics Appoints Vice President of Clinical and Regulatory Affairs

GI Dynamics® Inc. is pleased to announce the appointment of Stephen Linhares to the position of vice president of clinical and regulatory affairs.

January 3, 2019
·
4 min read
OrigiMed Completes Series B Round Focusing on Creating a Comprehensive Precision Medicine Platform for Oncology

OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the completion of its Series B financing. This round of financing is led by Grand Flight Investment. The pre-A financing investor Wedo Capital continued to invest.

January 3, 2019
·
2 min read
Business

Picosun and Nanexa Solidify Their Collaboration in Pharmaceutical ALD

Picosun Group and Nanexa AB solidify their collaboration in pharmaceutical ALD.

January 3, 2019
·
3 min read
Drug Development

Tiburio Launches With $31 Million and Two Compounds From Ipsen Targeting Rare Endocrine Diseases

New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.

January 3, 2019
·
3 min read
·
Alex Keown
Business

UroGen Taps Oncology Veteran Elizabeth Barrett as Its New CEO

Novartis and Pfizer veteran Elizabeth Barrett will take over as the new president and chief executive officer of UroGen Pharma Ltd. Barrett, who most recently helmed Novartis Oncology, will take over as Ron Bentsur steps down from his role as CEO.

January 3, 2019
·
2 min read
·
Alex Keown
Business

Merck Licenses NASH Compound From NGM Biopharma for $20 Million

MK-3655 is a monoclonal antibody agonist of the b-Klotho/FGFR1c receptor complex. The drug is being studied to treat nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

January 3, 2019
·
3 min read
·
Mark Terry
Deals

Ohr Pharma and NeuBase Merge to Push NeuBase’s Rare Disease Tech Platform

Ohr Pharmaceutical is merging with NeuBase Therapeutics to create a public company working to advance NeuBase’s peptide-nucleic acid (PNA) antisense olignonucleotide (PATrOL) tech platform.

January 3, 2019
·
2 min read
·
Mark Terry